ArticleAntiviral research2020
Topoisomerase III-β is required for efficient replication of positive-sense RNA viruses.
Open access · hybridAbstract read
In one paragraph
Article in Antiviral research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- Search for Specific Inhibitors Targeting Type IA Topoisomerases.Journal of molecular biology · 2026Review
- Furanoheliangolides fromJournal of natural products · 2025Article
- Substituted Triazole-3,5-Diamine Compounds as Novel Human Topoisomerase III Beta Inhibitors.International journal of molecular sciences · 2025Article
- Topoisomerase 3b facilitates piRNA biogenesis to promote transposon silencing and germ cell development.Cell reports · 2025Article
- Insights into the DNA and RNA Interactions of Human Topoisomerase III Beta Using Molecular Dynamics Simulations.Journal of chemical information and modeling · 2024Article
- Article
- Variation of Structure and Cellular Functions of Type IA Topoisomerases across the Tree of Life.Cells · 2024Review
- SCARF Genes in COVID-19 and Kidney Disease: A Path to Comorbidity-Specific Therapies.International journal of molecular sciences · 2023Review
- Identification and characterization of topoisomerase III beta poisons.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- A dual-activity topoisomerase complex promotes both transcriptional activation and repression in response to starvation.Nucleic acids research · 2023Article
- Topoisomerase 3b is dispensable for replication of a positive-sense RNA virus--murine coronavirus.Antiviral research · 2022Article
- Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases?International journal of molecular sciences · 2022Review
- Structural and biochemical basis for DNA and RNA catalysis by human Topoisomerase 3β.Nature communications · 2022Article
- SARS-CoV-2-host proteome interactions for antiviral drug discovery.Molecular systems biology · 2021Article
- Unravelling the mechanisms of Type 1A topoisomerases using single-molecule approaches.Nucleic acids research · 2021Review
- Serial co-expression analysis of host factors from SARS-CoV viruses highly converges with former high-throughput screenings and proposes key regulators.Briefings in bioinformatics · 2021Article
- A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection.Informatics in medicine unlocked · 2021Article
- Type IA Topoisomerases as Targets for Infectious Disease Treatments.Microorganisms · 2021Review
- Mechanism of Type IA Topoisomerases.Molecules (Basel, Switzerland) · 2020Review
- A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors.Cell reports · 2020Article
Corrections and comments
- Update of
Authors and funding
15 authors at 3 institutions in 2 countries.
K Reddisiva PrasanthDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Minato HiranoDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
W Samuel FaggDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Transplant Division, Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA.
Eileen T McAnarneyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Chao ShanDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Adam HageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Colette A PietzschDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Ricardo RajsbaumDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Institute of Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Institute of Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Mark T BedfordDepartment of Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center, Smithville, TX, USA.
Shelton S BradrickDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Institute of Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Vineet MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Mariano A Garcia-BlancoDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Institute of Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. Electronic address: maragarc@utmb.edu.
The University of Texas Medical Branch at Galveston · USDuke-NUS Medical School · SGThe University of Texas MD Anderson Cancer Center · US
Funding
Project 4 - Influenza - UABU19AI142759 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2019 to 2023
$37.5MRegulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1MEMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1MConsequences and mechanism of aberrant splicing in African American prostate cancer disparitiesR01CA204806 · NCI · GEORGE WASHINGTON UNIVERSITY · PI GARCIA-BLANCO, MARIANO A., LEE, NORMAN H · 2017 to 2021
$1.8MThe Functional Analysis of the Coactivator CARM1R01GM126421 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BEDFORD, MARK T. · 2018 to 2021
$1.4MCompetitive macrophage microRNA-RNA binding protein interactions in wound repairR01GM126412 · NIGMS · YALE UNIVERSITY · PI BENDER, JEFFREY R. · 2017 to 2020
$1.3MUnanchored Polyubiquitin Chains and Innate Immunity to Influenza VirusR21AI126012 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2017 to 2018
$426kNCI NIH HHS R01 CA204806NIAID NIH HHS R01 AI134907NIAID NIH HHS R21 AI126012NIAID NIH HHS T32 AI007526NIAID NIH HHS U19 AI142759NIGMS NIH HHS R01 GM126412NIGMS NIH HHS R01 GM126421
Abstract
Based on genome-scale loss-of-function screens we discovered that Topoisomerase III-β (TOP3B), a human topoisomerase that acts on DNA and RNA, is required for yellow fever virus and dengue virus-2 replication. Remarkably, we found that TOP3B is required for efficient replication of all positive-sense-single stranded RNA viruses tested, including SARS-CoV-2. While there are no drugs that specifically inhibit this topoisomerase, we posit that TOP3B is an attractive anti-viral target.
Indexed as
BetacoronavirusCell LineDengue VirusDNA Topoisomerases, Type IEbolavirusGene Knockout TechniquesHumansInfluenza A virusRNA VirusesSARS-CoV-2Virus ReplicationYellow fever virusZika VirusDNA Topoisomerases, Type ITOP3B protein, humanDengueHost factorPositive stranded RNA virusesSARS-CoV-2Topoisomerase III-ß (TOP3B)
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.